Biotech selected for UK incubator in Houston

Cambridge-based biotech SolasCure, developing a treatment to transform chronic wound care, has been selected for Innovate UK’s Global Incubator Programme in Houston, US. The programme is focused on commercialising innovative solutions for unmet healthcare needs and is delivered in partnership with the Texas Medical Centre (TMC), the largest medical complex globally. The programme will support the future entry of the company’s Aurase Wound Gel, its first investigational product, into the US market.

One of 16 healthcare companies selected, the Company’s participation in the programme builds on the recent European Innovation Council’s Accelerator Grant and Innovate UK Biomedical Catalyst Grant wins to further develop its lead product.

The 6-month Global Incubator Programme is fully funded by Innovate UK and includes two intensive market visits to Houston, a dynamic health research hub with over 1,760 life science companies, healthcare facilities and research institutions.

“It is a real boost to our journey at SolasCure to be selected for this Global Incubator Programme, continuing the momentum from our recent EIC Accelerator and the BMC grant wins. This represents another key piece of industry validation and recognition by TMC/TMC-Innovation, global leaders in medical innovation, that SolasCure has the potential to address a huge unmet need,” commented Lee Harle, Chief Executive Officer of SolasCure. “TMC is the largest medical complex in the world and gaining access to this expertise and network will be invaluable in strengthening our plans for SolasCure and Aurase Wound Gel in the US.”

More information online